Julie Passarell

1.2k total citations
38 papers, 909 citations indexed

About

Julie Passarell is a scholar working on Pharmacology, Psychiatry and Mental health and Infectious Diseases. According to data from OpenAlex, Julie Passarell has authored 38 papers receiving a total of 909 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pharmacology, 9 papers in Psychiatry and Mental health and 8 papers in Infectious Diseases. Recurrent topics in Julie Passarell's work include Antibiotics Pharmacokinetics and Efficacy (11 papers), Antimicrobial Resistance in Staphylococcus (6 papers) and Antibiotic Resistance in Bacteria (6 papers). Julie Passarell is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (11 papers), Antimicrobial Resistance in Staphylococcus (6 papers) and Antibiotic Resistance in Bacteria (6 papers). Julie Passarell collaborates with scholars based in United States, Belgium and Germany. Julie Passarell's co-authors include Paul G. Ambrose, Thaddeus H. Grasela, Phillip F. Pierce, Dennis M. Grasela, Howard Mayer, Jill Fiedler‐Kelly, Alison Meagher, Brenda Cirincione, Evelyn J. Ellis‐Grosse and Scott A. Van Wart and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Annals of the Rheumatic Diseases and Clinical Pharmacology & Therapeutics.

In The Last Decade

Julie Passarell

36 papers receiving 869 citations

Peers

Countries citing papers authored by Julie Passarell

Since Specialization

Citations

This map shows the geographic impact of Julie Passarell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Passarell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Passarell more than expected).

Fields of papers citing papers by Julie Passarell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Passarell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Passarell. The network helps show where Julie Passarell may publish in the future.

Co-authorship network of co-authors of Julie Passarell

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Passarell. A scholar is included among the top collaborators of Julie Passarell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Passarell. Julie Passarell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association Between Abatacept Exposure Levels and Infection Occurrence in Patients With Rheumatoid Arthritis: Post Hoc Analysis of the AVERT-2 Study 2025 ·The Journal of Rheumatology ·Paul Emery, R. Fleischmann, Robert Wong, (unknown), Yoshiya Tanaka, Vivian P. Bykerk, (unknown), T. Huizinga, Gustavo Citera, Vidya Perera, Bindu Murthy, (unknown), Julie Passarell, William D. Hedrich, Daphne Williams	0
2	Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2–4 Years with Rett Syndrome 2024 ·Advances in Therapy ·Mona Darwish, Julie Passarell, (unknown), Heather Bradley, Kathie M. Bishop, James M. Youakim	1
3	Population Pharmacokinetic Modeling to Support Trofinetide Dosing for the Treatment of Rett Syndrome 2024 ·Advances in Therapy ·Mona Darwish, Julie Passarell, (unknown), James M. Youakim, Heather Bradley, Kathie M. Bishop	1
4	Exposure–Response Efficacy Modeling to Support Trofinetide Dosing in Individuals with Rett Syndrome 2024 ·Advances in Therapy ·Mona Darwish, Julie Passarell, James M. Youakim, Heather Bradley, Kathie M. Bishop	5
5	Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19 2023 ·CPT Pharmacometrics & Systems Pharmacology ·Jennifer E. Sager, (unknown), Julie Passarell, (unknown), Xiaobin Li, Melissa Aldinger, (unknown), Andrew Skingsley, Elizabeth Alexander, Wendy W. Yeh, Erik Mogalian, (unknown), Amanda Peppercorn, Adrienne E. Shapiro, (unknown)	5
6	Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia 2022 ·Clinical Pharmacology in Drug Development ·Xiaofeng Wang, (unknown), (unknown), Julie Passarell, Suresh Mallikaarjun, (unknown)	13
7	Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis 2021 ·The Journal of Rheumatology ·Nicolino Ruperto, Hermine I. Brunner, Nikolay Tzaribachev, (unknown), Ingrid Louw, Rolando Cimaz, Jason Dare, Graciela Espada, Enrique Faugier Fuentes, M Ferrandiz, V. Gerloni, Pierre Quartier, Clóvis A. Silva, Linda Wagner‐Weiner, Yash Gandhi, Julie Passarell, Marleen Nys, Robert Wong, Alberto Martini, Daniel J. Lovell	4
8	Pharmacokinetic–pharmacodynamic (dipeptidyl peptidase‐4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once‐weekly administered omarigliptin 2019 ·British Journal of Clinical Pharmacology ·Lokesh Jain, Anne Chain, Daniel Tatosian, Jeremy Hing, Julie Passarell, Eunkyung Kauh, Eseng Lai	7
9	Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy 2017 ·Clinical Pharmacology Advances and Applications ·(unknown), Julie Passarell, Elizabeth Ludwig, Jill Fiedler‐Kelly, (unknown), Todd Grinnell, David Blum	1
10	Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections 2016 ·The Brazilian Journal of Infectious Diseases ·(unknown), Edward Fang, Philippe Prokocimer, Shawn D. Flanagan, Xu Zhu, (unknown), Toshiaki Tanaka, Julie Passarell, Jill Fiedler‐Kelly, Esteban C. Nannini	13
11	Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults 2015 ·Clinical Drug Investigation ·Seth C. Hopkins, (unknown), (unknown), Jeremy Hing, Julie Passarell, Antony Loebel, Kenneth S. Koblan	24
12	Nonclinical and Pharmacokinetic Assessments To Evaluate the Potential of Tedizolid and Linezolid To Affect Mitochondrial Function 2014 ·Antimicrobial Agents and Chemotherapy ·Shawn D. Flanagan, Edward E. McKee, (unknown), Paul M. Tulkens, (unknown), Jill Fiedler‐Kelly, Julie Passarell, Ann Radovsky, Philippe Prokocimer	78
13	Tedizolid Plasma Pharmacokinetics Are Comparable in Obese and Nonobese Patients and Healthy Subjects 2014 ·Shawn D. Flanagan, Sonia L. Minassian, Julie Passarell, Jill Fiedler‐Kelly, Philippe Prokocimer	3
14	Bendamustine pharmacokinetic profile and exposure–response relationships in patients with indolent non-Hodgkin’s lymphoma 2010 ·Cancer Chemotherapy and Pharmacology ·Joel Owen, Murad Melhem, Julie Passarell, Denise D’Andrea, Mona Darwish, (unknown)	47
15	Application of patient population-derived pharmacokinetic–pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci 2009 ·Diagnostic Microbiology and Infectious Disease ·Paul G. Ambrose, Alison Meagher, Julie Passarell, Scott A. Van Wart, Brenda Cirincione, Sujata M. Bhavnani, Evelyn J. Ellis‐Grosse	17
16	Exposure–response analyses of tigecycline tolerability in healthy subjects 2009 ·Diagnostic Microbiology and Infectious Disease ·Julie Passarell, Elizabeth Ludwig, (unknown), Alison Meagher, Thaddeus H. Grasela, Timothy Babinchak, Evelyn J. Ellis‐Grosse	12
17	Use of a clinically derived exposure–response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints 2008 ·Diagnostic Microbiology and Infectious Disease ·Paul G. Ambrose, Alison Meagher, Julie Passarell, Scott A. Van Wart, Brenda Cirincione, Chris Rubino, Joan Korth‐Bradley, Timothy Babinchak, Evelyn J. Ellis‐Grosse	13
18	Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment 2007 ·Cancer Chemotherapy and Pharmacology ·Gerald J. Fetterly, Joel Owen, Kim Stuyckens, Julie Passarell, Peter Zannikos, Arturo Soto-Matos, Miguel Izquierdo, Juan José Pérez Ruixo	31
19	Challenges in the transition to model-based development 2005 ·The AAPS Journal ·Thaddeus H. Grasela, Jill Fiedler‐Kelly, Cynthia A. Walawander, Joel Owen, Brenda Cirincione, (unknown), Elizabeth Ludwig, Julie Passarell, (unknown)	14
20	Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections 2001 ·Antimicrobial Agents and Chemotherapy ·Paul G. Ambrose, Dennis M. Grasela, Thaddeus H. Grasela, Julie Passarell, Howard Mayer, Phillip F. Pierce	237

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact